ABCG2 Polymorphisms in Multiple Myeloma
Posted: Wednesday, May 22, 2019
The risk of multiple myeloma may be associated with polymorphisms in ABCG2, according to a study by Marta Żebrowska-Nawrocka, PhD, and colleagues, of the University of Lodz, Poland. The study results, published in OncoTargets and Therapy, are reportedly the first to examine common polymorphisms of the ATP-binding cassette transporter, in the context of multiple myeloma in the Polish population.
In this single-center study, the peripheral blood DNA sequences of 181 Polish patients with multiple myeloma were compared with those of 97 healthy participants. The two most common ABCG2 polymorphism positions associated with reduced breast cancer resistant protein—G34A and C421A—were genotyped in both groups and compared.
Examination of the C421A position of ABCG2 revealed that the CA and AA genotypes occurred in 10.5% and 1.1% of patients with multiple myeloma, versus 2.1% and 0% of controls, respectively (P = .0218). Other factors such as age, gender, or type of immunoglobulin secreted were not associated with an increased risk for multiple myeloma. Similarly, no associations were found between multiple myeloma and polymorphisms in the G34A position.
“These results encourage further research into [single nucleotide polymorphism] C421A in the [breast cancer resistant protein] encoding gene and the risk of developing multiple myeloma,” the authors concluded. “The exact association between cancer susceptibility and ABCG2 polymorphisms remains unclear. The results appear to depend on the ethnic origin and type of cancer.”
Disclosure: The study authors reported no conflicts of interest.
